Neurocrine Biosciences
NBIX
246 hedge funds and large institutions have $4.34B invested in Neurocrine Biosciences in 2016 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 85 increasing their positions, 88 reducing their positions, and 24 closing their positions.
389% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $8.02M
67% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 24
12% more capital invested
Capital invested by funds: $3.86B → $4.34B (+$482M)
6% more funds holding
Funds holding: 232 → 246 (+14)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
3% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 88
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$49.4M |
| 2 |
Bank of New York Mellon
New York
|
+$49.3M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$38.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$23.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$25.2M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$22M |
| 3 |
HM
HealthCor Management
New York
|
-$20.5M |
| 4 |
PA
Perceptive Advisors
New York
|
-$16M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$13.6M |
NBIX Hedge Fund Activity: Q3 2016 in Review
246 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2016, worth a combined $4.34B — up 12% from $3.86B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new NBIX positions and 24 closed out — a net gain of 16 holders — while 85 added to existing stakes and 88 trimmed.
The largest buyer was Invesco, adding an estimated $49.4M. The largest seller was Millennium Management, cutting an estimated $25.2M.
- 246 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2016, up from 232 in Q2 2016.
- Funds reported $4.34B of Neurocrine Biosciences stock for Q3 2016, up 12% quarter-over-quarter.
- 40 funds opened new Neurocrine Biosciences positions in Q3 2016 and 24 closed out, a net change of +16 holders.
- The largest Neurocrine Biosciences buyer in Q3 2016 was Invesco, an estimated $49.4M added.
- The largest Neurocrine Biosciences seller in Q3 2016 was Millennium Management, an estimated $25.2M sold.
Based on aggregated 13F filings for Q3 2016.